Article

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): A randomised trial

The Lancet Oncology (Impact Factor: 24.69). 02/2014; 15(2). DOI: 10.1016/S1470-2045(13)70589-8

ABSTRACT

Background
Patients with isolated locoregional recurrences (ILRR) of breast cancer have a high risk of distant metastasis and death from breast cancer. We aimed to establish whether adjuvant chemotherapy improves the outcome of such patients.

Methods
The CALOR trial was a pragmatic, open-label, randomised trial that accrued patients with histologically proven and completely excised ILRR after unilateral breast cancer who had undergone a mastectomy or lumpectomy with clear surgical margins. Eligible patients were enrolled from hospitals worldwide and were centrally randomised (1:1) to chemotherapy (type selected by the investigator; multidrug for at least four courses recommended) or no chemotherapy, using permuted blocks, and stratified by previous chemotherapy, oestrogen-receptor and progesterone-receptor status, and location of ILRR. Patients with oestrogen-receptor-positive ILRR received adjuvant endocrine therapy, radiation therapy was mandated for patients with microscopically involved surgical margins, and anti-HER2 therapy was optional. The primary endpoint was disease-free survival. All analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00074152.

Findings
From Aug 22, 2003, to Jan 31, 2010, 85 patients were randomly assigned to receive chemotherapy and 77 were assigned to no chemotherapy. At a median follow-up of 4·9 years (IQR 3·6–6 ·0), 24 (28%) patients had disease-free survival events in the chemotherapy group compared with 34 (44%) in the no chemotherapy group. 5-year disease-free survival was 69% (95% CI 56–79) with chemotherapy versus 57% (44–67) without chemotherapy (hazard ratio 0·59 [95% CI 0·35–0·99]; p=0·046). Adjuvant chemotherapy was significantly more effective for women with oestrogen-receptor-negative ILRR (pinteraction=0·046), but analyses of disease-free survival according to the oestrogen-receptor status of the primary tumour were not statistically significant (pinteraction=0·43). Of the 81 patients who received chemotherapy, 12 (15%) had serious adverse events. The most common adverse events were neutropenia, febrile neutropenia, and intestinal infection.

Interpretation
Adjuvant chemotherapy should be recommended for patients with completely resected ILRR of breast cancer, especially if the recurrence is oestrogen-receptor negative.

Funding
US Department of Health and Human Services, Swiss Group for Clinical Cancer Research (SAKK), Frontier Science and Technology Research Foundation, Australian and New Zealand Breast Cancer Trials Group, Swedish Cancer Society, Oncosuisse, Cancer Association of South Africa, Foundation for Clinical Research of Eastern Switzerland (OSKK), Grupo Español de Investigación en Cáncer de Mama (GEICAM), and the Dutch Breast Cancer Trialists' Group (BOOG).

Download full-text

Full-text

Available from: Irene Wapnir, Feb 25, 2014

  • No preview · Article · Jan 2014 · The Lancet Oncology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nach kompletter Resektion eines lokalen Rezidivs profitieren vor allem Patientinnen mit Östrogenrezeptor-negativem Brustkrebsrezidiv von einer adjuvanten Chemotherapie. Ohne Chemotherapie leben fünf Jahre nach der Therapie weniger Patientinnen krankheitsfrei. So das Ergebnis der CALOR-Studie, an der 162 Frauen mit unilateralem Mammakarzinom nach Mastektomie oder Lumpektomie teilnahmen, deren lokoregionäres Rezidiv komplett reseziert worden war.Randomisiert erhielten die Studienteilnehmerinnen eine Chemotherapie (n = 81) oder keine (n = 77). Das Chemotherapie-Regime wählte jeweils der behandelnde Arzt. Bei 110 von 143 Patientinnen mit bekanntem Östrogenrezeptor-Status des Lokalrezidivs war dieser positiv. Den primären Studienendpunkt bildete das krankheitsfreie Überleben, den sekundären Endpunkt das Gesamtüberleben.Nach fünf Jahren lebten mehr Patientinnen der Chemotherapie-Gruppe noch ohne Zeichen einer erneuten Krebserkrankung (69 vs. 57 %; Hazard Ratio [HR] 0,59; p = 0,046). Auch das ...
    No preview · Article · Mar 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adjuvant systemic therapy significantly reduces rates of distant recurrence and death. The effect of systemic therapy is not limited to reducing distant recurrences but also extends to reducing loco-regional recurrences, and rates of loco-regional recurrence have steadily declined over the past 25 years. This review focuses on the effect of adjuvant systemic therapy on rates of ipsilateral breast tumor recurrence following lumpectomy plus breast irradiation in several pivotal NSABP trials in early-stage breast cancer. J. Surg. Oncol. © 2014 Wiley Periodicals, Inc.
    No preview · Article · Jul 2014 · Journal of Surgical Oncology
Show more